Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4–6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR ant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Liu, Qiuli, Tong, Dali, Liu, Gaolei, Xu, Jing, Do, Khang, Geary, Kyla, Zhang, Dianzheng, Zhang, Jun, Zhang, Yao, Li, Yaoming, Bi, Gang, Lan, Weihua, Jiang, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596596/
https://ncbi.nlm.nih.gov/pubmed/28837141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2017.417
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados